
==== Front
Antibodies (Basel)
Antibodies (Basel)
antibodies
Antibodies
2073-4468
MDPI

10.3390/antib13030076
antibodies-13-00076
Review
Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules
https://orcid.org/0000-0001-9298-6783
Ferrara Francesco 1*
https://orcid.org/0000-0002-9671-5507
Verduci Chiara 2
Laconi Emanuela 3
https://orcid.org/0000-0002-5084-5808
Mangione Andrea 4
https://orcid.org/0000-0001-5093-7596
Dondi Chiara 5
Del Vecchio Marta 5
https://orcid.org/0009-0004-5570-2293
Carlevatti Veronica 6
https://orcid.org/0000-0002-6528-2171
Zovi Andrea 7
https://orcid.org/0000-0001-9488-6057
Capuozzo Maurizio 1
Langella Roberto 8
Hufton Simon E. Academic Editor
1 Pharmaceutical Department, Asl Napoli 3 Sud, Dell’amicizia Street 72, 80035 Nola, Italy; m.capuozzo@aslnapoli3sud.it
2 IRCCS Humanitas Research Hospital, Manzoni Street 56, 20089 Rozzano, Italy; verducichiara92@gmail.com
3 Pharmaceutical Department, ASST Nord Milano, E. Bassini Hospital, Massimo Gorki Street 50, 20092 Cinisello Balsamo, Italy; emanuela.laconi@asst-nordmilano.it
4 Pharmaceutical Department, ASST Valle Olona, Busto Arsizio Hospital, Arnaldo da Brescia 1 Street, 21052 Busto Arsizio, Italy; andrea.mangione.1@gmail.com
5 Pharmaceutical Department, ASST Ovest Milanese, Legnano Hospital, Papa Giovanni Paolo II Street, 20025 Legnano, Italy; chiara.dondi95@gmail.com (C.D.); delvecchiomarta@gmail.com (M.D.V.)
6 Hospital Pharmacy Department, ASST Fatebenefratelli-Sacco, V. Buzzi Hospital, Castelvetro Street 28, 20154 Milano, Italy; veronica.carlevatti@asst-fbf-sacco.it
7 Ministry of Health, Viale Giorgio Ribotta 5, 00144 Rome, Italy; zovi.andrea@gmail.com
8 Italian Society of Hospital Pharmacy (SIFO), SIFO Secretariat of the Lombardy Region, Via Carlo Farini 81, 20159 Milan, Italy; roberto.langella87@gmail.com
* Correspondence: f.ferrara@aslnapoli3sud.it
14 9 2024
9 2024
13 3 7621 8 2024
07 9 2024
10 9 2024
© 2024 by the authors.
2024
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Psoriasis is a persistent, inflammatory condition affecting millions globally, marked by excessive keratinocyte proliferation, immune cell infiltration, and widespread inflammation. Over the years, therapeutic approaches have developed significantly, shifting from conventional topical treatments and phototherapy to more sophisticated systemic interventions such as biologics and, recently, oral small-molecule drugs. This review seeks to present a comprehensive investigation of the existing psoriasis treatment options, focusing on biologic agents, oral small molecules, and emerging treatments. Several categories of biologic treatments have received regulatory approval for psoriasis, including TNF-α, IL-17, IL-12/23, and IL-23 inhibitors. Biologics have revolutionized the treatment of psoriasis. These targeted therapies offer significant improvement in disease control and quality of life, with acceptable safety profiles. However, limitations such as cost, potential immunogenicity, and administration challenges have driven the exploration of alternative treatment modalities. Oral small molecules, particularly inhibitors of Janus kinase (JAK), have emerged as options due to their convenience and efficacy. These agents represent a paradigm shift in the management of the condition, offering oral administration and targeted action on specific signaling pathways. In addition to existing therapies, the review explores emerging treatments that hold promise for the future of psoriasis care. These include innovative small-molecule inhibitors. Early-stage clinical trials suggest these agents may enhance outcomes for psoriasis patients. In conclusion, the therapeutic landscape of psoriasis is rapidly evolving, emphasizing targeted, patient-centered treatments. Ongoing research and development are expected to lead to more personalized and effective management strategies for this complex condition.

psoriasis
inhibitors
plaque psoriasis
JAK/STAT
IL-17
IL-23
This research received no external funding.
==== Body
pmc1. Introduction

Psoriasis, a multifactorial and chronic skin disease mediated by biological defense mechanisms, commonly affects 3% of the general population [1]. It is linked with significant comorbidities, productivity loss, work limitations, and healthcare costs exceeding USD 40 billion annually [2]. Many studies in the literature have indicated that the prevalence of psoriasis ranges from approximately 30 cases per 100,000 inhabitants to about 320 cases per 100,000 inhabitants. This condition demonstrates correlations with factors such as age, gender, and ethnic background, as well as a variety of genetic and environmental influences [3,4,5]. This persistent negative impact on quality of life and financial burden underscores the necessity for effective long-term disease management. Disease severity is influenced by factors such as lesion extent, localization, and associated conditions like psoriatic arthritis [6,7]. Successful treatment involves achieving either remission or near remission, correlating with enhanced quality of life. Moreover, an increasing body of research has suggested that psoriasis represents a systemic condition with various accompanying illnesses, including cardiovascular ailments, psoriatic arthritis, metabolic syndrome, depression, and anxiety [8,9]. Hence, it is imperative to address both the comorbidities associated with psoriasis and the disease itself in order to devise timely intervention and treatment approaches. Recent years have seen the development of highly effective targeted therapies, including conventional, biological, and oral small-molecule treatments. These biological therapies encompass various classes, such as tumor necrosis factor (TNF)-α inhibitors (e.g., etanercept, adalimumab, golimumab, certolizumab pegol, and infliximab), Interleukin (IL)-17 inhibitors (e.g., brodalumab, ixekizumab, and secukinumab), IL-23 inhibitors (e.g., Risankizumab, tildrakizumab, and guselkumab), and IL-12/23 inhibitor (ustekinumab) [10,11,12]. While these innovations have elevated treatment efficacy and safety standards, there remains a demand for novel therapies enabling superior skin remission and durability. Furthermore, many treatments experience declining efficacy over time, necessitating the exploration of alternative options. Recent advances in understanding psoriasis pathophysiology have spurred the development of additional therapeutic targets, including IL-36 inhibitors, phosphodiesterase (PDE)-4 inhibitors, Janus kinase (JAK) inhibitors, tyrosine kinase 2 (TYK2) inhibitors, RORγt inhibitors, and A3 adenosine receptor agonists [13,14,15]. This narrative review explores the latest progress in biologicals, oral small molecules, and new biosimilar drugs for psoriasis treatment.

This review aims to discuss all treatments for moderate to severe psoriasis, starting with biological drugs and monoclonal antibodies and extending to the most recent oral treatments with small molecules. The metabolic aspect is discussed briefly to introduce the pathology and then to address the actual pharmacological treatment. Obsolete treatments, such as rarely used oral medications for moderate to severe forms, as well as topical treatments with creams that have no systemic curative role but only symptomatic relief, are not considered. To date, the efficacy and effectiveness of each drug can vary based on the patient’s clinical conditions, making it impossible to evaluate or prefer one drug over another universally. The patient’s clinical conditions and those related to therapeutic appropriateness, along with associated costs, must always be considered by the prescribing physician. For example, in treatment-naive patients, etanercept or adalimumab, which now also have biosimilar drugs available, should always be used as first-line treatments when efficacy is equal, compared to newer, higher-cost drugs.

2. Currently Available Biologic Therapy for Psoriasis

The outcomes derived from numerous genome-wide association studies (GWAS) and clinical trials corroborate the pivotal involvement of TNF/IL-17/IL-23 signaling pathways in the psoriasis etiology [16,17,18,19]. TNF-α serves as a crucial inflammatory cytokine highly evolved in psoriatic lesions, playing a central role in the development of psoriasis. This significance is underscored by the effectiveness of therapies targeting TNF-α [20,21,22]. Produced by various cell types associated with psoriasis, including keratinocytes, neutrophils, dendritic cells (DCs), mast cells, and Th22 cells, Th17, and NKT [23,24], TNF-α exhibits dual effects. On one hand, it notably inhibits plasmacytoid DCs from secreting interferon (IFN)-α [25], often resulting in exacerbated or paradoxical psoriasis during TNF-α inhibitor treatment [26]. Conversely, TNF-α promotes pDCs’ maturation into a more dendritic cell phenotype, facilitating the production of IL-23 [27]. Additionally, TNF-α stimulates the synthesis of IL-18 and IL-12, potent inducers of IFN-γ, thereby contributing to the regulation of the Th1 response [28]. Moreover, TNF-α acts with IL-17A, co-regulating cytokines and keratinocyte genes associated with psoriasis and influencing keratinocyte function [29]. These observations collectively indicate TNF-α‘s pivotal role as a key regulator within the IL-23/IL-17 axis. IL-23 is a heterodimeric protein primarily secreted by DCs, whose levels are elevated in psoriasis [30]. Within psoriatic lesions, the concentration of IL-23 protein notably surpasses that found in unaffected skin [31,32]. Consequently, it can be deduced that IL-23 is intimately linked to the pathogenesis of psoriasis. IL-23 influences T cells through its actions, particularly CD4+ helper T cells (Th17 cells), via a cellular receptor complex [33]. Subsequently, IL-23 stimulates the secretion of IL-17, another crucial cytokine implicated in psoriasis, by Th17 cells through the activation of signaling pathways [34]. The IL-17 family encompasses six structurally akin cytokines, spanning from IL-17A to IL-17F [35]. Investigations have noted IL-17A as the cytokine with the greatest biological activity, exhibiting the highest concentration in psoriasis [36,37,38]. Consequently, IL-17A, also recognized as IL-17, has garnered substantial interest due to its pro-inflammatory characteristics and involvement in autoimmune disorders [39]. The secretion of IL-17, particularly IL-17A and IL-17F, predominantly exerts direct effects on keratinocytes, inducing the synthesis of various molecules such as β-defensins, antimicrobial peptides (AMPs), and cytokines. Additionally, IL-17 stimulates the production of chemokines which are often elevated in psoriatic lesions to recruit neutrophils, lymphocytes, and macrophages [40]. Furthermore, IL-17 has been implicated in promoting keratinocyte proliferation [41]. Psoriasis entails a sophisticated web of interactions among diverse cellular components and molecular entities. At the heart of disease advancement lies the intricate interplay between the adaptive and innate immune systems. This dynamic dialogue triggers the synthesis of numerous cytokines, which uphold characteristic psoriatic manifestations in both the dermis and epidermis. Additionally, keratinocytes contribute to inflammation and local activation. Other pathways implicated in psoriasis, such as CCL20-CCR6, the IL-36/IL-1 pathway, the IFN pathway, and others involving cytokines like IL-22 and IL-6, are under investigation as potential targets for new drug development. A schematic representation of all these interconnections is shown in Figure 1.

2.1. TNF-α Inhibitors

The currently approved and available TNF-α inhibitors include etanercept, infliximab, adalimumab, certolizumab, and golimumab [42,43,44]. Etanercept received approval from the US Food and Drug Administration (FDA) in November 1998 as the first anti-tumor necrosis factor agent for the treatment of moderate to severe rheumatoid arthritis (RA) (217). In comparison to etanercept, infliximab has shown a faster and more pronounced response in the early stages of therapy (218). Furthermore, infliximab is effective in resolving skin lesions and reducing joint pain in patients with psoriatic arthritis (PsA) [45]. Adalimumab is an important treatment option for adults with moderate to severe chronic plaque psoriasis and also provides a promising systemic treatment alternative for children and adolescents aged 4 years and older [46]. Certolizumab pegol offers pharmacokinetic benefits due to its lack of an Fc region, which results in minimal placental transfer, low infant exposure during lactation, and reduced oral bioavailability [47]. As a result, certolizumab is a valuable option for the treatment of moderate to severe plaque psoriasis, especially in women of reproductive age. Golimumab, a fully human monoclonal antibody with a bivalent Fab region, shows higher affinity for both soluble and transmembrane forms of the TNF-α protein compared to infliximab and adalimumab, effectively decreasing circulating levels of TNF-α protein and reducing its binding to receptors [48]. Additionally, golimumab has lower immunogenicity than other TNF-α inhibitors. However, treatment with adalimumab has been associated with adverse events such as thrombocytopenia and leukopenia [49]. Table 1 summarizes all recent phase II, III, and IV clinical trials involving anti-TNF-α biologic agents used in the management of psoriasis.

2.2. IL-23 Inhibitors

Monoclonal antibodies targeting IL-23 exhibit a direct inhibitory effect on the production of cytokines associated with psoriasis. Currently, IL-23 antagonists such as guselkumab, tildrakizumab, risankizumab, and mirikizumab are prominent in this field. Guselkumab gained FDA approval in 2017 as the first IL-23 inhibitor for treating moderate to severe plaque psoriasis. Its efficacy has been validated across various psoriasis types [50,51]. The VOYAGE 1/2 trials, the initial phase III investigations into guselkumab for psoriasis treatment, involved randomizing patients to receive either guselkumab or adalimumab (administered at 100 mg in weeks 0 and 4 and every 8 weeks). Results indicated significant efficacy with 85% of guselkumab users achieving an Investigator Global Assessment (IGA) score of 0 or 1 by week 16, along with a 73% Psoriasis Area and Severity Index (PASI) 90 response rate, surpassing placebo and adalimumab. Adverse reaction incidence did not significantly differ from other treatments [52]. Tildrakizumab, a humanized monoclonal antibody, has demonstrated sustained efficacy and favorable tolerability in improving plaque psoriatic lesions. It exhibits minimal impact on cardiometabolic risk factors, suggesting a favorable safety profile [53]. Cost-effectiveness analyses position tildrakizumab as one of the most economical first-line treatments for moderate to severe psoriasis [54]. Similarly, risankizumab, an IgG1 monoclonal antibody targeting the p19 subunit of IL-23, exhibits superior therapeutic efficacy compared to ustekinumab and adalimumab [55]. It appears to offer improved efficacy and reduced risk compared to other biologics targeting IL-23 p19, IL-12/IL-23 p40, and IL-17 [56]. In Table 2, all the most recent phase II, III, and IV clinical studies concerning IL-23 inhibitors used for the management of psoriasis are summarized.

2.3. IL-17 Inhibitors

The IL-17 cytokine pathway plays a pivotal role in psoriasis pathogenesis, and targeting IL-17 or its receptors with inhibitors represents an effective treatment strategy. Three biologic agents sanctioned by the FDA for psoriasis treatment operate through this pathway, including two monoclonal antibodies with high IL-17A affinity: secukinumab and ixekizumab. Secukinumab, the pioneer monoclonal antibody in this category, received FDA approval in 2015 for psoriasis management [57]. Clinical trials have demonstrated its efficacy in reversing plaque psoriasis histopathology by curbing IL-17A production, thereby facilitating plaque resolution. Notably, pivotal studies like ERASURE and FIXTURE reported impressive PASI 75 response rates, with 77.1% to 81.6% of patients achieving this milestone after receiving 300 mg of secukinumab and 67.0% to 71.6% with 150 mg at week 12 [58]. Beyond plaque psoriasis, secukinumab has shown efficacy in treating nail psoriasis and psoriatic arthritis. Additionally, compared to adalimumab, secukinumab exhibits superior treatment retention in psoriatic arthritis management [59]. Ixekizumab, employing a mechanism akin to secukinumab, exhibits comparable efficacy in psoriasis treatment. Notably, a phase III trial showcased that a minimum of 87.0% of patients with moderate-to-severe plaque psoriasis attained a PASI 75 response with continuous ixekizumab treatment. Additionally, ixekizumab demonstrates superiority over etanercept in clinical efficacy. However, adverse events including infection, headache, neutropenia, and inflammatory bowel disease have been associated with both secukinumab and ixekizumab [60]. Apart from IL-17A inhibitors, brodalumab, targeting IL-17RA directly, has shown efficacy in psoriasis treatment. Phase III trials (AMAGINE-2 and AMAGINE-3) reported PASI 75 response rates of 85.0% and 86.0%, respectively, following biweekly subcutaneous administration of brodalumab. Brodalumab also shows efficacy in treating psoriatic arthritis [61]. Among the IL-17 antibodies approved by the FDA, bimekizumab, a monoclonal IgG1 antibody and the first dual inhibitor of IL-17F and IL-17A, received FDA approval in October 2023. In a multicenter, double-blind, placebo-controlled, randomized phase III trial (BE READY), 91% of patients with plaque psoriasis achieved a PASI 90 response at 16 weeks with bimekizumab, demonstrating quicker and more robust effects than prior IL-17 and IL-23 inhibitors. Additionally, bimekizumab provides significant response rates, with sustained improvement of skin and joint symptoms lasting up to 56 weeks [62]. Recent studies indicate comparable efficacy between bimekizumab and adalimumab for the treatment of psoriatic arthritis and plaque psoriasis, with bimekizumab achieving superior skin clearance compared to secukinumab. However, bimekizumab is associated with an increased risk of oral candidiasis, highlighting the need for further research to balance therapeutic efficacy with safety considerations [63,64]. Table 3 provides a summary of all recent phase II, III, and IV clinical trials involving IL-17 inhibitors for the management of psoriasis.

2.4. Additional Interleukin Inhibitors Employed in Psoriasis

Ustekinumab received FDA approval for psoriasis treatment in 2009, marking it as the only IL-12/IL-23p40 inhibitor for this condition [65]. This monoclonal antibody targets the shared p40 subunit of IL-12 and IL-23, thereby blocking the signaling pathways activated by ligand–receptor interactions. Clinical trials PHOENIX 1 and PHOENIX 2 demonstrated 12-week PASI 75 response rates of 66.7% and 67.1% with the 45 mg dose and 66.4% and 75.7% with the 90 mg dose (administered at week 0, week 4, and every 12 weeks thereafter). Ustekinumab also exhibits sustained efficacy, maintaining significant response rates even three years after treatment initiation [66,67]. Comparative studies show that ustekinumab achieves higher response rates than etanercept but lower rates than brodalumab following 12 weeks of standard psoriasis therapy at therapeutic doses [68]. An additional critical pharmacological target in psoriasis treatment is the IL-36/IL-1 axis. This pathway is crucial in the pathogenesis of psoriasis, especially in generalized pustular psoriasis (GPP). Currently, two monoclonal antibodies, imsidolimab and spesolimab, have shown significant efficacy in global clinical trials involving GPP patients [69]. Notably, spesolimab is a novel, selective, humanized antibody targeting IL-36R, representing the first therapeutic agent specifically aimed at the IL-36 pathway for acute GPP treatment. In a phase I trial involving seven subjects, all patients who received a single intravenous dose of spesolimab (10 mg/kg) exhibited rapid lesion improvement within 4 weeks [70]. These findings were supported by the phase II Effisayil-1 trial, which demonstrated that 85% of patients with moderate to severe acute GPP had no visible pustules on their skin after 12 weeks of treatment, and 80% experienced significant remission or complete resolution of skin symptoms [71]. Conversely, the GALLOP phase II trial highlighted the effectiveness of imsidolimab, and this investigation has progressed to phase III based on these promising results [72]. Other anti-IL-1 agents, such as anakinra, gevokizumab, and canakinumab, have also shown promising results in psoriasis treatment [73,74,75]. However, additional large-scale, prospective, randomized clinical trials are needed to confirm the efficacy and safety of these treatments for acute GPP. Furthermore, a significant reduction in IL-8 levels has been observed in refractory psoriatic arthritis patients treated with exogenous IL-36Ra, underscoring the importance of the IL-36 axis in the inflammatory pathways of this condition. Nevertheless, there is a lack of clinical evidence demonstrating the effectiveness of IL-36R-targeted therapies in psoriatic arthritis.

3. New and Emerging Oral Small Molecules

In the intricate realm of exploring fresh oral compounds for treating psoriasis, the JAK-STAT pathway emerges as a central player. This signaling route plays a pivotal role in cytokine transmission, fueling inflammation across various autoimmune disorders, thus making it a substantial therapeutic focal point [76]. This pathway orchestrates the activity of numerous cytokines prevalent in psoriasis, including interferon-α, -β, and -γ. Given its pivotal role in psoriasis pathogenesis, there’s a burgeoning interest in exploring novel JAK-STAT inhibitors, complementing those already in use and showcasing promising outcomes, to validate their efficacy in managing this condition [77]. Consequently, multiple ongoing clinical inquiries are meticulously scrutinizing the efficacy and safety profiles of these fresh inhibitors in the realm of psoriasis (Figure 2).

Some medications that have already received approval for psoriasis management and inhibit this pathway are classified as first-generation. For example, tofacitinib, an inhibitor that disrupts the JAK signaling pathway, thereby substantially alleviating all psoriasis-related symptoms, also received full FDA approval following a number of events related to its safety. Prescribability of this drug is possible with appropriate clinical monitoring of the patient. Although tofacitinib outperformed placebo in the treatment of psoriasis, it is not FDA-approved for this specific application due to concerns about its clinical efficacy and long-term safety [78]. Various studies have verified its advantages, and notably, a phase III trial indicated that over 50% of patients on a regimen of 5 mg tofacitinib twice daily and more than 60% of patients on 10 mg twice daily achieved a significant improvement [79]. Another case is upadacitinib, approved in 2022 for psoriatic arthritis, which has demonstrated good results in terms of effectiveness and safety in clinical research. Yet, there are currently no trials planned to assess its effectiveness and safety for psoriasis [80,81]. On the other hand, baricitinib and ruxolitinib target the same pathway and function by inducing Th17 cell apoptosis; both of these are first-generation JAK inhibitors that effectively treat psoriasis [82]. Nevertheless, a careful examination of the safety profile and adverse effects of these drugs is essential, as all first-generation JAK inhibitors target the kinase region of various JAK proteins, heightening the risk of nausea, infections, hemoglobin reduction, and potential gastrointestinal perforation [83]. In Table 4, all the most recent phase II, III, and IV clinical studies concerning JAK inhibitors used for the management of psoriasis are summarized.

Second-generation JAK inhibitors have the capability to selectively target specific JAK proteins without impacting other cytokines; for instance, deucravacitinib (authorized by the FDA in 2022) has targeted effects on TYK2 [84,85]. A recent randomized, double-blind, placebo-controlled phase III trial demonstrated a remarkable therapeutic response after 16 weeks of daily oral administration of deucravacitinib at a dose of 6 mg, when compared to patients who received either placebo [86]. PF-06826647 represents a novel TYK2 inhibitor that recently concluded its phase II trial aimed at assessing its safety and effectiveness in patients with moderate to severe plaque psoriasis [87]. During its initial human study, adverse events and alterations in PASI scores were evaluated in 40 plaque psoriasis patients. These patients were randomly assigned to receive either a placebo or PF-06826647 (400 mg) once daily for a period of 28 days. Notably, patients receiving 100 mg and 400 mg doses of PF-06826647 experienced mean decreases of −14.62 and −24.18 in PASI scores from baseline, respectively, in comparison to −11.13 observed in the placebo group [88,89]. Brepocitinib, a potent TYK2/JAK1 selective inhibitor, is being developed for psoriasis treatment. A phase I trial with 30 patients showed dose-dependent efficacy trends, with higher response rates and greater reductions in PASI scores in the 30 mg and 100 mg brepocitinib groups compared to placebo. Treatment-emergent adverse events were mild, with no serious adverse events reported. Phase II trials further validated brepocitinib’s efficacy, showing significant improvements in PASI scores and response rates compared to placebo across various treatment regimens. Safety data indicated a low risk of treatment-emergent adverse events, primarily mild and treatment-related, with common adverse events including headache, psoriasis exacerbation, and upper respiratory tract infections [90]. While the majority of selective JAK inhibitors are still under scientific investigation and have not yet received market approval, they are viewed as promising therapeutic agents due to their enhanced safety profile. Other potential oral therapies include piclidenoson (CF101), an agonist of the adenosine A3 receptor, which has been found to be overexpressed in inflammatory conditions such as psoriasis or other autoimmune diseases. Preliminary studies have demonstrated its efficacy, but particularly, a very recent study (double-blind phase 3 COMFORT-1 trial randomized-NCT03168256) conducted on 529 patients showed that piclidenoson demonstrated efficacy responses that increased over time alongside a favorable safety profile [91]. These results provide further justification for its ongoing clinical advancement as a treatment for psoriasis. Belumosudil (KD025), a Rho-associated kinase (ROCK2) selective inhibitor, shows efficacy in patients with psoriasis vulgaris. In particular, in an interesting study, some researchers have demonstrated that treatment with belumosulid resulted in a 50% reduction in psoriasis area and severity index PASI scores in 46% of patients. This treatment also led to decreased epidermal thickness and T-cell infiltration in the skin. Additionally, significant reductions in IL-17 and IL-23 levels were observed, along with increased IL-10 levels in responders. These findings indicate that oral administration of belumosulid effectively downregulates the Th17-driven autoimmune response and improves clinical symptoms in psoriatic patients by modulating cytokine levels without adversely affecting the immune system [92]. Vimirogant (VTP-43742) is a potent, selective, and orally active RORγt inhibitor that has shown promising efficacy in phase II trials for patients with plaque psoriasis but has also been linked to certain adverse events [93]. Currently, in another study conducted on patients with moderate to severe plaque psoriasis, another orally active RORγt inverse agonist called Cedirogant (ABBV-157) has shown promising results [94]. Recent scientific studies are also focusing on PDE4, which, having demonstrated powerful anti-inflammatory activity, is drawing the attention of many scientists for the potential involvement of its inhibitors in treating various skin disorders such as psoriasis [95]. In 2014, the oral PDE4 inhibitor apremilast was approved in the United States for adult patients with moderate to severe plaque psoriasis. A clinical study (PALACE 1) demonstrated that apremilast (30 mg twice daily) achieved a response rate double that of the control group given placebo [96]. Another phase III clinical trial (ESTEEM 1) showed the efficacy of apremilast in moderate to severe plaque psoriasis, with even higher response rates compared to placebo [97]. Despite these promising findings, the use of PDE4 inhibitors in psoriasis treatment has been hampered by side effects such as emesis. As researchers continue to explore this therapeutic target, there is hope that ongoing investigations will unlock its full potential and offer new avenues for improving patient outcomes.

Recent research indicates that IL-23, produced by CD301b+ cells, can drive the local proliferation of TRM cells, suggesting that IL-23 inhibitors or new treatments targeting CD301b may provide a promising approach for managing disease relapse and sustaining therapeutic effects. Nonetheless, translating these novel therapeutic strategies into clinical practice requires further investigation. While considerable progress has been made in understanding and treating psoriasis, many aspects remain unexplored. A crucial future objective is to develop effective therapies for managing psoriasis comorbidities, particularly metabolic and cardiovascular disorders [98].

4. Conclusions and Prospects

Psoriasis is a chronic inflammatory skin condition that imposes a significant burden on both individuals and healthcare systems, underscoring the urgent need for a comprehensive understanding of the mechanisms driving the disease’s pathogenesis. In the past decade, advances in understanding the immunopathology and pathogenesis of psoriasis have led to significant therapeutic innovations. Targeted biologic therapies have introduced new possibilities for patients, offering substantial disease modification and potentially even curative outcomes by preventing the accumulation of tissue-resident memory T cells in the skin. However, challenges persist in managing psoriasis, including the side effects of medications and the risk of disease relapse following treatment discontinuation. Prolonged use of certain drugs may lead to adverse effects and the development of immune tolerance, thereby limiting their long-term efficacy. Furthermore, the high cost of these therapies often impacts the sustainability of national healthcare systems. A deeper understanding of the mechanisms behind disease recurrence highlights the importance of early intervention to prevent the onset and proliferation of tissue-resident memory T cells. Special attention is also needed for rarer subtypes of psoriasis, such as palmoplantar and pustular psoriasis, which often show limited response to conventional treatments. Additionally, despite the identification of numerous potential metabolic molecules, a thorough understanding of psoriasis’s metabolic effects is still lacking. With the advent of advanced tools like single-cell metabolomics and spatial metabolomics, it will be possible to construct a comprehensive metabolic network of psoriasis through innovative algorithms and integrated analyses. Targeted metabolic therapies are still in their infancy, likely due to metabolic variability, flexibility, and unpredictable side effects. Identifying more effective metabolic targets will be a critical step forward. We anticipate that focusing on psoriasis metabolism and establishing a metabolism-centered psoriasis network will become a prominent research topic in the near future. An important area for future investigation involves evaluating the potential of genetic biomarkers as early indicators for psoriasis, which could facilitate earlier diagnosis and more precise intervention strategies.

Author Contributions

Conceptualization, F.F. and M.C.; methodology, M.C.; validation, R.L., A.Z. and F.F.; formal analysis, C.D.; investigation, C.V.; resources, E.L.; data curation, A.M.; writing—original draft preparation, M.D.V.; writing—review and editing, V.C.; visualization, R.L.; supervision, A.Z.; project administration, F.F. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Full availability of data and materials. All stated data can be provided on request to the reader.

Conflicts of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare that the opinions expressed are of a personal nature and do not in any way commit the responsibility of the Administrations to which they belong.

Figure 1 The interplay of cytokine pathways in psoriasis. A sophisticated web connects the fundamental molecules involved in the development of psoriasis. This interconnection is regarded as pivotal for advancement. On one front, the reciprocal enhancement of the adaptive and innate immune systems generates multiple cytokines and sustains characteristic psoriatic traits in both the dermis and epidermis. Conversely, keratinocytes foster the mediators and bolster the proliferation of activation.

Figure 2 A schematic figure of the JAK/STAT pathway illustrating the mechanism of action of JAK inhibitors. P is the chemical symbol for phosphorus.

antibodies-13-00076-t001_Table 1 Table 1 Biological targeting TNF-α in the management of psoriasis. The table summarizes all treatments and the NCT code to further explore potential therapeutic developments.

Drug Name	Indication	Phase	NCT	
Adalimumab	Plaque psoriasis	III	NCT05073315	
Adalimumab	Moderate/severe plaque psoriasis	III	NCT02762955	
Adalimumab	Plaque psoriasis	III	NCT03316781	
Adalimumab	Chronic plaque psoriasis	III	NCT02581345	
Adalimumab	Psoriasis, sleep apnea, obstructive	IV	NCT01181570	
Adalimumab	Psoriasis, cardiovascular disease	IV	NCT01866592	
Adalimumab	Psoriasis, cardiovascular disease	IV	NCT03082729	
Certolizumab	Chronic plaque psoriasis, psoriasis	II	NCT00245765	
Certolizumab	Chronic plaque psoriasis, psoriasis	II	NCT00329303	
Etanercept	Psoriasis	IV	NCT01971346	
Infliximab	Psoriatic arthritis	IV	NCT00432406	

antibodies-13-00076-t002_Table 2 Table 2 Biological agents targeting IL-23 employed in the management of psoriasis. The table summarizes all treatments and the NCT code to further explore potential therapeutic developments.

Drug Name	Indication	Phase	NCT	
Guselkumab	Psoriasis	IV	NCT05858632	
Guselkumab	Psoriasis	IV	NCT05004727	
Mirikizumab	Plaque psoriasis	II	NCT02899988	
Mirikizumab	Psoriasis	III	NCT03482011	
Risankizumab	Psoriasis	II	NCT05283135	
Risankizumab	Moderate to severe plaque psoriasis	III	NCT03255382	
Risankizumab	Psoriasis	IV	NCT04630652	
Tildrakizumab	Psoriasis vulgaris	IV	NCT04541329	
Tildrakizumab	Psoriasis vulgaris	IV	NCT05390515	
Tildrakizumab	Psoriasis	IV	NCT05110313	
Tildrakizumab	Psoriasis	IV	NCT04271540	

antibodies-13-00076-t003_Table 3 Table 3 Biological agents targeting IL-17 employed in the management of psoriasis. The table summarizes all treatments and the NCT code to further explore potential therapeutic developments.

Drug Name	Indication	Phase	NCT	
Bimekizumab	Psoriasis	IV	NCT04340076	
Brodalumab	Psoriasis vulgaris	IV	NCT04306315	
Brodalumab	Psoriasis vulgaris	IV	NCT03331835	
Ixekizumab	Psoriasis (moderate to severe)	II	NCT01107457	
Secukinumab	Psoriasis	II	NCT02483234	
Secukinumab	Moderate to severe plaque-type psoriasis	III	NCT01365455	
Secukinumab	Moderate to severe plaque-type psoriasis	III	NCT01544595	

antibodies-13-00076-t004_Table 4 Table 4 Small molecules approved in the management of psoriasis. The table summarizes all treatments and the NCT code to further explore potential therapeutic developments.

Drug Name	Indication	Phase	NCT	
Abrocitinib	Plaque psoriasis	II	NCT02201524	
Baricitinib	Plaque psoriasis	II	NCT01490632	
Peficitinib	Plaque psoriasis	II	NCT01096862	
Ruxolitinib	Plaque psoriasis	II	NCT00820950	
Ruxolitinib	Plaque psoriasis	II	NCT00778700	
Ruxolitinib	Plaque psoriasis	II	NCT00617994	
Tofacitinib	Plaque psoriasis	II	NCT01710046	
Tofacitinib	Psoriasis, psoriasis vulgaris	II	NCT01831466	
Tofacitinib	Plaque psoriasis	III	NCT01815424	
Tofacitinib	Plaque psoriasis	III	NCT01309737	
Tofacitinib	Psoriasis	III	NCT01163253	
Tofacitinib	Psoriasis	III	NCT01519089	

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
==== Refs
References

1. Brożyna A.A. Slominski R.M. Nedoszytko B. Zmijewski M.A. Slominski A.T. Vitamin D Signaling in Psoriasis: Pathogenesis and Therapy Int. J. Mol. Sci. 2022 23 8575 10.3390/ijms23158575 35955731
2. Evans C. Managed care aspects of psoriasis and psoriatic arthritis Am. J Manag. Care 2016 22 (Suppl. S8) s238 s243 27356195
3. Parisi R. Iskandar I.Y.K. Kontopantelis E. Augustin M. Griffiths C.E.M. Ashcroft D.M. Global Psoriasis Atlas National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study BMJ 2020 369 m1590 10.1136/bmj.m1590 32467098
4. Damiani G. Bragazzi N.L. Aksut C.K. Wu D. Alicandro G. McGonagle D. Guo C. Dellavalle R. Grada A. Wong P. The Global, Regional, and National Burden of Psoriasis: Results and Insights from the Global Burden of Disease 2019 Study Front. Med. 2021 8 743180 10.3389/fmed.2021.743180
5. Cao F. Liu Y.-C. Ni Q.-Y. Chen Y. Wan C.-H. Liu S.-Y. Tao L.-M. Jiang Z.-X. Ni J. Pan H.-F. Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019 Autoimmun. Rev. 2023 22 103359 10.1016/j.autrev.2023.103359 37201621
6. Toledano E. García de Yébenes M.J. González-Álvaro I. Carmona L. Severity indices in rheumatoid arthritis: A systematic review Reumatol. Clin. 2019 15 146 151 10.1016/j.reuma.2017.07.004 28807652
7. Eldjoudi D.A. Barreal A.C. Gonzalez-Rodríguez M. Ruiz-Fernández C. Farrag Y. Farrag M. Lago F. Capuozzo M. Gonzalez-Gay M.A. Varela A.M. Leptin in Osteoarthritis and Rheumatoid Arthritis: Player or Bystander? Int. J. Mol. Sci. 2022 23 2859 10.3390/ijms23052859 35270000
8. Armstrong A.W. Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review JAMA 2020 323 1945 1960 10.1001/jama.2020.4006 32427307
9. Cassalia F. Cazzaniga S. Ofenloch R. Elsner P. Gonçalo M. Schuttelaar M.-L. Svensson Å. Pezzolo E. Bruze M. Naldi L. Comparison of Perceptions of Skin Condition, Product Use and Allergen Reactivity Between People with Psoriasis and Controls in the European Dermato-Epidemiology Network (EDEN) Fragrance Study Acta Derm.-Venereol. 2024 104 adv23513 10.2340/actadv.v104.23513 38436432
10. Ghoreschi K. Balato A. Enerbäck C. Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis Lancet 2021 397 754 766 10.1016/S0140-6736(21)00184-7 33515492
11. Boutet M.-A. Nerviani A. Gallo Afflitto G. Pitzalis C. Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints Int. J. Mol. Sci. 2018 19 530 10.3390/ijms19020530 29425183
12. Capuozzo M. Ottaiano A. Nava E. Cascone S. Fico R. Iaffaioli R.V. Cinque C. Etanercept induces remission of polyarteritis nodosa: A case report Front. Pharmacol. 2014 5 122 10.3389/fphar.2014.00122 24917817
13. Ruiz-Ponce M. Cuesta-López L. Montilla L. Pérez-Sánchez C. Ortiz-Buitrago P. Barranco A. Gahete M.D. Herman-Sánchez N. Lucendo A. Navarro P. Decoding clinical and molecular pathways of liver dysfunction in Psoriatic Arthritis: Impact of cumulative methotrexate doses Biomed. Pharmacother. 2023 168 115779 10.1016/j.biopha.2023.115779 37913737
14. Mease P.J. A Deodhar A. van der Heijde D. Behrens F. Kivitz A.J. Neal J. Kim J. Singhal S. Nowak M. Banerjee S. Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis Ann. Rheum. Dis. 2022 81 815 822 10.1136/annrheumdis-2021-221664 35241426
15. Zhang M. Iwata S. Sonomoto K. Ueno M. Fujita Y. Anan J. Miyazaki Y. Ohkubo N. Sumikawa M.H. Todoroki Y. mTOR activation in CD8+ cells contributes to disease activity of rheumatoid arthritis and increases therapeutic response to TNF inhibitors Rheumatology 2022 61 3010 3022 10.1093/rheumatology/keab834 34791054
16. Nair R.P. Ruether A. Stuart P.E. Jenisch S. Tejasvi T. Hiremagalore R. Schreiber S. Kabelitz D. Lim H.W. Voorhees J.J. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis J. Investig. Dermatol. 2008 128 1653 1661 10.1038/sj.jid.5701255 18219280
17. Merola J.F. Landewé R. McInnes I.B. Mease P.J. Ritchlin C.T. Tanaka Y. Asahina A. Behrens F. Gladman D.D. Gossec L. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: A randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE) Lancet 2023 401 38 48 10.1016/S0140-6736(22)02303-0 36495881
18. Mahmoud A.M. Meta-analysis and GRADE assessment of randomized controlled trials on the efficacy and safety of bimekizumab in psoriatic arthritis patients Curr. Med. Res. Opin. 2023 39 1031 1043 10.1080/03007995.2023.2228613 37345857
19. Coates L.C. Landewé R. McInnes I.B. Mease P.J. Ritchlin C.T. Tanaka Y. Asahina A. Behrens F. Gladman D.D. Gossec L. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL RMD Open 2024 10 e003855 10.1136/rmdopen-2023-003855 38388171
20. Lee A. Scott L.J. Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis BioDrugs 2020 34 235 244 10.1007/s40259-020-00416-z 32207094
21. Daprà V. Ponti R. Curcio G.L. Archetti M. Dini M. Gavatorta M. Quaglino P. Fierro M.T. Bergallo M. Functional study of TNF-α as a promoter of polymorphisms in psoriasis Ital. J. Dermatol. Venereol. 2022 157 146 153 10.23736/S2784-8671.21.06979-0 33982552
22. Sbidian E. Chaimani A. Garcia-Doval I. Do G. Hua C. Mazaud C. Droitcourt C. Hughes C. Ingram J.R. Naldi L. Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis Cochrane Database Syst. Rev. 2017 12 CD011535 10.1002/14651858.CD011535.pub2 29271481
23. Hu P. Wang M. Gao H. Zheng A. Li J. Mu D. Tong J. The Role of Helper T Cells in Psoriasis Front. Immunol. 2021 12 788940 10.3389/fimmu.2021.788940 34975883
24. Furiati S.C. Catarino J.S. Silva M.V. Silva R.F. Estevam R.B. Teodoro R.B. Pereira S.L. Ataide M. Rodrigues V. Rodrigues D.B.R. Th1, Th17, and Treg Responses are Differently Modulated by TNF-α Inhibitors and Methotrexate in Psoriasis Patients Sci. Rep. 2019 9 7526 10.1038/s41598-019-43899-9 31101850
25. Psarras A. Antanaviciute A. Alase A. Carr I. Wittmann M. Emery P. Tsokos G.C. Vital E.M. TNF-α Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-α Production and Enhancing T Cell Activation J. Immunol. 2021 206 785 796 10.4049/jimmunol.1901358 33441439
26. Elyoussfi S. Thomas B.J. Ciurtin C. Tailored treatment options for patients with psoriatic arthritis and psoriasis: Review of established and new biologic and small molecule therapies Rheumatol. Int. 2016 36 603 612 10.1007/s00296-016-3436-0 26892034
27. Benezeder T. Bordag N. Woltsche J. Teufelberger A. Perchthaler I. Weger W. Salmhofer W. Gruber-Wackernagel A. Painsi C. Zhan Q. Mast cells express IL17A, IL17F and RORC, are activated and persist with IL-17 production in resolved skin of patients with chronic plaque-type psoriasis Preprint 2024 rs.3.rs-3958361 10.21203/rs.3.rs-3958361/v1
28. Tittes J. Brell J. Fritz P. Jonak C. Stary G. Ressler J.M. Künig S. Weninger W. Stöckl J. Regulation of the Immune Cell Repertoire in Psoriasis Patients Upon Blockade of IL-17A or TNFα Dermatol. Ther. 2024 14 613 626 10.1007/s13555-024-01112-4
29. Kamata M. Tada Y. Crosstalk: Keratinocytes and immune cells in psoriasis Front. Immunol. 2023 14 1286344 10.3389/fimmu.2023.1286344 38022549
30. Zhang X. Li X. Wang Y. Chen Y. Hu Y. Guo C. Yu Z. Xu P. Ding Y. Mi Q.-S. Abnormal lipid metabolism in epidermal Langerhans cells mediates psoriasis-like dermatitis J. Clin. Investig. 2022 7 e150223 10.1172/jci.insight.150223
31. Ruggiero A. Megna M. Fabbrocini G. Ocampo-Garza S.S. Anti-IL23 biologic therapies in the treatment of psoriasis: Real-world experience versus clinical trials data Immunol. Res. 2023 71 328 355 10.1007/s12026-022-09356-y 36598647
32. González-Rodríguez M. Edjoudi D.A. Barreal A.C. Ruiz-Fernández C. Farrag M. González-Rodríguez B. Lago F. Capuozzo M. Gonzalez-Gay M.A. Varela A.M. Progranulin in Musculoskeletal Inflammatory and Degenerative Disorders, Focus on Rheumatoid Arthritis, Lupus and Intervertebral Disc Disease: A Systematic Review Pharmaceuticals 2022 15 1544 10.3390/ph15121544 36558994
33. Li Y. Yu X. Ma Y. Hua S. IL-23 and dendritic cells: What are the roles of their mutual attachment in immune response and immunotherapy? Cytokine 2019 120 78 84 10.1016/j.cyto.2019.02.018 31029042
34. Liu T. Li S. Ying S. Tang S. Ding Y. Li Y. Qiao J. Fang H. The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside Front. Immunol. 2020 11 594735 10.3389/fimmu.2020.594735 33281823
35. Gu C. Wu L. Li X. IL-17 family: Cytokines, receptors and signaling Cytokine 2013 64 477 485 10.1016/j.cyto.2013.07.022 24011563
36. Przepiórka-Kosińska J. Bartosińska J. Raczkiewicz D. Bojar I. Kosiński J. Krasowska D. Chodorowska G. Serum concentration of osteopontin and interleukin 17 in psoriatic patients Adv. Clin. Exp. Med. 2020 29 203 208 10.17219/acem/112604 32109010
37. Michalak-Stoma A. Bartosińska J. Kowal M. Raczkiewicz D. Krasowska D. Chodorowska G. IL-17A in the Psoriatic Patients’ Serum and Plaque Scales as Potential Marker of the Diseases Severity and Obesity Mediat. Inflamm. 2020 2020 7420823 10.1155/2020/7420823
38. Jiang X. Zhou R. Zhang Y. Zhu T. Li Q. Zhang W. Interleukin-17 as a potential therapeutic target for chronic pain Front. Immunol. 2022 13 999407 10.3389/fimmu.2022.999407 36248896
39. Fouser L.A. Wright J.F. Dunussi-Joannopoulos K. Collins M. Th17 cytokines and their emerging roles in inflammation and autoimmunity Immunol. Rev. 2008 226 87 102 10.1111/j.1600-065X.2008.00712.x 19161418
40. Furue M. Furue K. Tsuji G. Nakahara T. Interleukin-17A and Keratinocytes in Psoriasis Int. J. Mol. Sci. 2020 21 1275 10.3390/ijms21041275 32070069
41. Mercurio L. Failla C.M. Capriotti L. Scarponi C. Facchiano F. Morelli M. Rossi S. Pagnanelli G. Albanesi C. Cavani A. Interleukin (IL)-17/IL-36 axis participates to the crosstalk between endothelial cells and keratinocytes during inflammatory skin responses PLoS ONE 2020 15 e0222969 10.1371/journal.pone.0222969 32352958
42. Chao R. Kavanaugh A. Psoriatic Arthritis: Newer and Older Therapies Curr. Rheumatol. Rep. 2019 21 75 10.1007/s11926-019-0866-1 31865449
43. Lu X. Hu R. Peng L. Liu M. Sun Z. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis Front. Immunol. 2021 12 638444 10.3389/fimmu.2021.638444 33889152
44. Blauvelt A. Reich K. Lebwohl M. Burge D. Arendt C. Peterson L. Drew J. Rolleri R. Gottlieb A.B. Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: Pooled analysis of week 16 data from three randomized controlled trials J. Eur. Acad. Dermatol. Venereol. 2019 33 546 552 10.1111/jdv.15258 30242918
45. Pelechas E. Drosos A.A. Etanercept biosimilar SB-4 Expert Opin. Biol. Ther. 2019 19 173 179 10.1080/14712598.2019.1566456 30616405
46. Madani A. Almuhaideb Q. Adalimumab Therapy in a Patient with Psoriasis, Down Syndrome, and Concomitant Hepatitis B Virus Infection Biologics 2021 15 375 378 10.2147/BTT.S317888 34511879
47. Carubbi F. Fidanza R. Palmieri M. Ventura A. Tambone S. Cipriani P. Giacomelli R. Fargnoli M.C. Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis J. Dermatol. Treat. 2020 31 692 697 10.1080/09546634.2019.1605143
48. Oldfield V. Plosker G.L. Golimumab: In the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis BioDrugs 2009 23 125 135 10.2165/00063030-200923020-00005 19489653
49. Yuk J.-M. Kim J.K. Kim I.S. Jo E.-K. TNF in Human Tuberculosis: A Double-Edged Sword Immune Netw. 2024 24 e4 10.4110/in.2024.24.e4 38455468
50. Markham A. Guselkumab: First Global Approval Drugs 2017 77 1487 1492 10.1007/s40265-017-0800-7 28819723
51. Ritchlin C.T. Helliwell P.S. Boehncke W.-H. Soriano E.R. Hsia E.C. Kollmeier A.P. Chakravarty S.D. Zazzetti F. A Subramanian R. Xu X.L. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced RMD Open 2021 7 e001457 10.1136/rmdopen-2020-001457 33568556
52. Sonkoly E. Maul J.-T. Megna M. Gorecki P. Crombag E. Buyze J. Savage L. Guselkumab in Patients with Scalp Psoriasis: A post hoc Analysis of the VOYAGE 2 Phase III Randomized Clinical Trial Acta Derm.-Venereol. 2024 104 adv18672 10.2340/actadv.v104.18672 38436429
53. Lebwohl M.G. Leonardi C.L. Mehta N.N. Gottlieb A.B. Mendelsohn A.M. Parno J. Rozzo S.J. Menter M.A. Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2) J. Am. Acad. Dermatol. 2021 84 398 407 10.1016/j.jaad.2020.09.047 32961255
54. Jia X. Zhao Y. Carrico J. Brodtkorb T.-H. Mendelsohn A.M. Lowry S. Feldman S. Wu J.J. Armstrong A.W. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States J. Dermatol. Treat. 2022 33 740 748 10.1080/09546634.2020.1773382 32602762
55. Reich K. Gooderham M. Thaçi D. Crowley J.J. Ryan C. Krueger J.G. Tsai T.-F. Flack M. Gu Y. A Williams D. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomised, double-blind, active-comparator-controlled phase 3 trial Lancet 2019 394 576 586 10.1016/S0140-6736(19)30952-3 31280967
56. Sbidian E. Chaimani A. Guelimi R. Garcia-Doval I. Hua C. Hughes C. Naldi L. Kinberger M. Afach S. Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis Cochrane Database Syst. Rev. 2023 2023 CD011535 10.1002/14651858.CD011535.pub2
57. Krueger J.G. Wharton K.A. Jr. Schlitt T. Suprun M. Torene R.I. Jiang X. Wang C.Q. Fuentes-Duculan J. Hartmann N. Peters T. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis J. Allergy Clin. Immunol. 2019 144 750 763 10.1016/j.jaci.2019.04.029 31129129
58. Langley R.G. Sofen H. Dei-Cas I. Reich K. Sigurgeirsson B. Warren R.B. Paul C. Szepietowski J.C. Tsai T.-F. Hampele I. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: Results of a randomized extension of the phase III ERASURE and FIXTURE trials Br. J. Dermatol. 2023 188 198 207 10.1093/bjd/ljac040 36763857
59. Blauvelt A. Papp K.A. Griffiths C.E.M. Puig L. Weisman J. Dutronc Y. Kerr L.F. Ilo D. Mallbris L. Augustin M. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) Am. J. Clin. Dermatol. 2017 18 273 280 10.1007/s40257-016-0246-9 28074446
60. Menter A. Warren R. Langley R. Merola J. Kerr L. Dennehy E. Shrom D. Amato D. Okubo Y. Reich K. Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: Results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3) J. Eur. Acad. Dermatol. Venereol. 2017 31 1686 1692 10.1111/jdv.14237 28322474
61. McMichael A. Desai S.R. Qureshi A. Rastogi S. Alexis A.F. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials Am. J. Clin. Dermatol. 2019 20 267 276 10.1007/s40257-018-0408-z 30471012
62. Gordon K.B. Foley P. Krueger J.G. Pinter A. Reich K. Vender R. Vanvoorden V. Madden C. White K. Cioffi C. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): A multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial Lancet 2021 397 475 486 10.1016/S0140-6736(21)00126-4 33549192
63. Reich K. Warren R.B. Lebwohl M. Gooderham M. Strober B. Langley R.G. Paul C. De Cuyper D. Vanvoorden V. Madden C. Bimekizumab versus Secukinumab in Plaque Psoriasis N. Engl. J. Med. 2021 385 142 152 10.1056/NEJMoa2102383 33891380
64. Warren R.B. Blauvelt A. Bagel J. Papp K.A. Yamauchi P. Armstrong A. Langley R.G. Vanvoorden V. De Cuyper D. Cioffi C. Bimekizumab versus Adalimumab in Plaque Psoriasis N. Engl. J. Med. 2021 385 130 141 10.1056/NEJMoa2102388 33891379
65. Van De Kerkhof P. Novel biologic therapies in development targeting IL-12/IL-23 J. Eur. Acad. Dermatol. Venereol. 2010 24 (Suppl. S6) 5 9 10.1111/j.1468-3083.2010.03830.x 20831703
66. Leonardi C.L. Kimball A.B. A Papp K. Yeilding N. Guzzo C. Wang Y. Li S. Dooley L.T. Gordon K.B. PHOENIX 1 study investigators Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 2008 371 1665 1674 10.1016/S0140-6736(08)60725-4 18486739
67. A Papp K. Langley R.G. Lebwohl M. Krueger G.G. Szapary P. Yeilding N. Guzzo C. Hsu M.-C. Wang Y. Li S. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet 2008 371 1675 1684 10.1016/S0140-6736(08)60726-6 18486740
68. A Alzahrani S. Alzamil F.M. Aljuhni A.M. A Al Thaqfan N. Alqahtani N.Y. A Alwarwari S. A Alkharashi A. A Alzabadin R. A Alzehairi R. A Alhajlah A. A Systematic Review Evaluating the Effectiveness of Several Biological Therapies for the Treatment of Skin Psoriasis Cureus 2023 15 e50588 10.7759/cureus.50588 38222196
69. Iznardo H. Puig L. The interleukin-1 family cytokines in psoriasis: Pathogenetic role and therapeutic perspectives Expert Rev. Clin. Immunol. 2021 17 187 199 10.1080/1744666X.2021.1886081 33538202
70. Burden A.D. Spesolimab, an interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis Expert Rev. Clin. Immunol. 2023 19 473 481 10.1080/1744666X.2023.2195165 36960829
71. Tsai T.-F. Zheng M. Ding Y. Song Z. Liu Q. Chen Y. Hu H. Xu J. Efficacy and Safety of Spesolimab in Patients with Generalized Pustular Psoriasis: A Subgroup Analysis of Chinese Patients in the Effisayil 1 Trial Dermatol. Ther. 2023 13 3097 3110 10.1007/s13555-023-01037-4
72. Fukaura R. Akiyama M. Targeting IL-36 in Inflammatory Skin Diseases BioDrugs 2023 37 279 293 10.1007/s40259-023-00587-5 36867370
73. Yatsuzuka K. Murakami M. Response to the article by Naik et al. entitled “anakinra for refractory pustular psoriasis: A phase II, open label, dose-escalation trial” J. Am. Acad. Dermatol. 2023 88 e145 e146 10.1016/j.jaad.2022.10.058 36372378
74. Seishima M. Fujii K. Mizutani Y. Generalized Pustular Psoriasis in Pregnancy: Current and Future Treatments Am. J. Clin. Dermatol. 2022 23 661 671 10.1007/s40257-022-00698-9 35704168
75. Mansouri B. Kivelevitch D. Campa M. Menter A. Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumab Clin. Exp. Dermatol. 2016 41 324 326 10.1111/ced.12759 26344848
76. Ferrara F. Zovi A. Capuozzo M. Langella R. Atopic dermatitis: Treatment and innovations in immunotherapy Inflammopharmacology 2024 32 1777 1789 10.1007/s10787-024-01453-8 38581639
77. Ferrara F. Zovi A. Capuozzo M. Montero J.G. Zavaleta-Monestel E. Langella R. Innovative Immunotherapy for the Treatment of Atopic Dermatitis: Focus on the European and Latin American Regulatory Frameworks Curr. Dermatol. Rep. 2024 13 55 66 10.1007/s13671-024-00423-1
78. Kivitz A.J. FitzGerald O. Nash P. Pang S. Azevedo V.F. Wang C. Takiya L. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: Post hoc exploratory analysis from two phase III trials Clin. Rheumatol. 2022 41 499 511 10.1007/s10067-021-05894-2 34510295
79. Dai Q. Zhang Y. Liu Q. Zhang C. Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: A systematic review and meta-analysis of randomized controlled trials Clin. Rheumatol. 2024 43 1605 1613 10.1007/s10067-024-06940-5 38517652
80. Fleischmann R. Pangan A.L. Song I. Mysler E. Bessette L. Peterfy C. Durez P. Ostor A.J. Li Y. Zhou Y. Upadacitinib Versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial Arthritis Rheumatol. 2019 71 1788 1800 10.1002/art.41032 31287230
81. Conaghan P.G. Mysler E. Tanaka Y. Da Silva-Tillmann B. Shaw T. Liu J. Ferguson R. Enejosa J.V. Cohen S. Nash P. Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program Drug Saf. 2021 44 515 530 10.1007/s40264-020-01036-w 33527177
82. Guo J. Zhang H. Lin W. Lu L. Su J. Chen X. Signaling pathways and targeted therapies for psoriasis Signal Transduct. Target. Ther. 2023 8 437 10.1038/s41392-023-01655-6 38008779
83. Chimalakonda A. Burke J. Cheng L. Catlett I. Tagen M. Zhao Q. Patel A. Shen J. Girgis I.G. Banerjee S. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors Dermatol. Ther. 2021 11 1763 1776 10.1007/s13555-021-00596-8 34471993
84. Krueger J.G. McInnes I.B. Blauvelt A. Tyrosine kinase 2 and Janus kinase—signal transducer and activator of transcription signaling and inhibition in plaque psoriasis J. Am. Acad. Dermatol. 2022 86 148 157 10.1016/j.jaad.2021.06.869 34224773
85. Loo W.J. Turchin I. Prajapati V.H. Gooderham M.J. Grewal P. Hong C.-H. Sauder M. Vender R.B. Maari C. Papp K.A. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway J. Cutan. Med. Surg. 2023 27 (Suppl. S1) 3S 24S 10.1177/12034754221141680 36519621
86. Armstrong A.W. Gooderham M. Warren R.B. Papp K.A. Strober B. Thaçi D. Morita A. Szepietowski J.C. Imafuku S. Colston E. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial J. Am. Acad. Dermatol. 2023 88 29 39 10.1016/j.jaad.2022.07.002 35820547
87. Martin G. Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors Dermatol. Ther. 2023 13 417 435 10.1007/s13555-022-00878-9
88. Singh R.S.P. Pradhan V. Roberts E.S. Scaramozza M. Kieras E. Gale J.D. Peeva E. Vincent M.S. Banerjee A. Fensome A. Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF-06826647: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study Clin. Transl. Sci. 2021 14 671 682 10.1111/cts.12929 33290616
89. Tehlirian C. Peeva E. Kieras E. Scaramozza M. Roberts E.S. Singh R.S.P. Pradhan V. Banerjee A. Garcet S. Xi L. Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: A phase 1, randomised, double-blind, placebo-controlled, parallel-group study Lancet Rheumatol. 2021 3 e204 e213 10.1016/S2665-9913(20)30397-0 38279383
90. Forman S.B. Pariser D.M. Poulin Y. Vincent M.S. Gilbert S.A. Kieras E.M. Qiu R. Yu D. Papacharalambous J. Tehlirian C. TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial J. Investig. Dermatol. 2020 140 2359 2370.e5 10.1016/j.jid.2020.03.962 32311398
91. Papp K.A. Beyska-Rizova S. Gantcheva M.L. Simeonova E.S. Brezoev P. Celic M. Groppa L. Blicharski T. Selmanagic A. Kalicka-Dudzik M. Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1) J. Eur. Acad. Dermatol. Venereol. 2024 38 1112 1120 10.1111/jdv.19811 38279575
92. Zanin-Zhorov A. Weiss J.M. Trzeciak A. Chen W. Zhang J. Nyuydzefe M.S. Arencibia C. Polimera S. Schueller O. Fuentes-Duculan J. Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10 J. Immunol. 2017 198 3809 3814 10.4049/jimmunol.1602142 28389592
93. Pandya V.B. Kumar S. Sachchidanand S. Sharma R. Desai R.C. Combating Autoimmune Diseases with Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc) Inhibitors: Hits and Misses J. Med. Chem. 2018 61 10976 10995 10.1021/acs.jmedchem.8b00588 30010338
94. Gege C. Retinoic acid-related orphan receptor gamma t (RORγt) inverse agonists/antagonists for the treatment of inflammatory diseases—Where are we presently? Expert Opin. Drug Discov. 2021 16 1517 1535 10.1080/17460441.2021.1948833 34192992
95. Li G. He D. Cai X. Guan W. Zhang Y. Wu J.-Q. Yao H. Advances in the development of phosphodiesterase-4 inhibitors Eur. J. Med. Chem. 2023 250 115195 10.1016/j.ejmech.2023.115195 36809706
96. Mease P.J. Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis Rheumatol. Ther. 2014 1 1 20 10.1007/s40744-014-0005-4 27747762
97. Papp K. Reich K. Leonardi C.L. Kircik L. Chimenti S. Langley R.G. Hu C. Stevens R.M. Day R.M. Gordon K.B. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) J. Am. Acad. Dermatol. 2015 73 37 49 10.1016/j.jaad.2015.03.049 26089047
98. Bissonnette R. Pinter A. Ferris L.K. Gerdes S. Rich P. Vender R. Miller M. Shen Y.-K. Kannan A. Li S. An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis N. Engl. J. Med. 2024 390 510 521 10.1056/NEJMoa2308713 38324484
